Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2021

01-06-2021 | Fatty Liver | Original Article

Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank

Authors: Biyao Zou, Yee Hui Yeo, Ramsey Cheung, Erik Ingelsson, Mindie H. Nguyen

Published in: Digestive Diseases and Sciences | Issue 6/2021

Login to get access

Abstract

Background

Nonalcoholic fatty liver disease is common and is associated with rising morbidity and mortality in the UK. Cardiovascular disease is the main cause of death in people with nonalcoholic fatty liver disease.

Aims

To determine the association between baseline cardiovascular risk factors with fatty liver index, and to investigate the association between fatty liver index and the incidence of cardiovascular disease in the UK.

Methods

This study is a population-based retrospective cohort study using the UK Biobank database.

Results

The mean fatty liver index in the study cohort was 44.9, and 33.7% met the criteria for nonalcoholic fatty liver disease. Fatty liver index was significantly associated with a wide range of cardiovascular risk factors at baseline. During a mean follow-up of 7.86 years, the combined incidence of cardiovascular disease was 6.92 per 1000-person years at risk. We found significant association between fatty liver index and incident cardiovascular disease in the fully adjusted model. We found significant association between fatty liver index and incident cardiovascular disease in subgroups stratified by BMI as well as subgroups with fatty liver index < 30, < 60, and ≥ 60.

Conclusions

Fatty liver index not only predicts NAFLD diagnosis, but also indicates baseline and future development of cardiovascular disease on long-term follow-up across weight categories and fatty liver index spectrum. These findings can inform clinicians and other stakeholders on cardiovascular disease management and preventive efforts. Patients with high fatty liver index should be counseled on the increased future risk of developing cardiovascular disease.
Literature
1.
go back to reference Rinella ME, Sanyal AJ. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol 2015;12:65–66.CrossRef Rinella ME, Sanyal AJ. NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD. Nat Rev Gastroenterol Hepatol 2015;12:65–66.CrossRef
2.
go back to reference Williams R, Aspinall R, Bellis M et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet (London, England) 2014;384:1953–1997.CrossRef Williams R, Aspinall R, Bellis M et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet (London, England) 2014;384:1953–1997.CrossRef
3.
go back to reference Wong VW, Chu WC, Wong GL et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–415.CrossRef Wong VW, Chu WC, Wong GL et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61:409–415.CrossRef
4.
go back to reference Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–131.CrossRef Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–131.CrossRef
5.
go back to reference Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 2013;178:38–45.CrossRef Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 2013;178:38–45.CrossRef
6.
go back to reference Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012;47:586–595.CrossRef Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012;47:586–595.CrossRef
7.
go back to reference Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md) 2016;64:73–84.CrossRef Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md) 2016;64:73–84.CrossRef
8.
go back to reference Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11–20.CrossRef Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11–20.CrossRef
9.
go back to reference Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology (Baltimore, Md) 2018;67:123–133.CrossRef Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology (Baltimore, Md) 2018;67:123–133.CrossRef
10.
go back to reference Li J, Zou B, Yeo YH et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389–398.CrossRef Li J, Zou B, Yeo YH et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389–398.CrossRef
11.
go back to reference Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology (Baltimore, Md) 2010;51:595–602.CrossRef Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology (Baltimore, Md) 2010;51:595–602.CrossRef
12.
go back to reference Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 2015;35:221–235.CrossRef Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 2015;35:221–235.CrossRef
13.
go back to reference Ekstedt M, Hagstrom H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (Baltimore, Md) 2015;61:1547–1554.CrossRef Ekstedt M, Hagstrom H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (Baltimore, Md) 2015;61:1547–1554.CrossRef
14.
go back to reference Angulo P, Kleiner DE, Dam-Larsen S et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397.e310.CrossRef Angulo P, Kleiner DE, Dam-Larsen S et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397.e310.CrossRef
15.
go back to reference Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM. The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:291–304.CrossRef Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM. The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:291–304.CrossRef
16.
go back to reference Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2020. Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of nonalcoholic fatty liver disease. Hepatology (Baltimore, Md). 2020.
17.
go back to reference Alexander M, Loomis AK, van der Lei J et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ (Clin Res Ed) 2019;367:l5367. Alexander M, Loomis AK, van der Lei J et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ (Clin Res Ed) 2019;367:l5367.
18.
go back to reference Sinn DH, Kang D, Chang Y, et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. J Gastroenterol Hepatol. 2019. Sinn DH, Kang D, Chang Y, et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. J Gastroenterol Hepatol. 2019.
19.
go back to reference Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.CrossRef Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.CrossRef
21.
go back to reference Tikkanen E, Gustafsson S, Ingelsson E. Associations of fitness, physical activity, strength, and genetic risk with cardiovascular disease: longitudinal analyses in the UK biobank study. Circulation 2018;137:2583–2591.CrossRef Tikkanen E, Gustafsson S, Ingelsson E. Associations of fitness, physical activity, strength, and genetic risk with cardiovascular disease: longitudinal analyses in the UK biobank study. Circulation 2018;137:2583–2591.CrossRef
22.
go back to reference Zanetti D, Bergman H, Burgess S, Assimes TL, Bhalla V, Ingelsson E. Urinary albumin, sodium, and potassium and cardiovascular outcomes in the UK biobank: observational and mendelian randomization analyses. Hypertension 2020;75:714–722.CrossRef Zanetti D, Bergman H, Burgess S, Assimes TL, Bhalla V, Ingelsson E. Urinary albumin, sodium, and potassium and cardiovascular outcomes in the UK biobank: observational and mendelian randomization analyses. Hypertension 2020;75:714–722.CrossRef
24.
go back to reference Speliotes EK, Massaro JM, Hoffmann U et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology (Baltimore, Md) 2010;51:1979–1987.CrossRef Speliotes EK, Massaro JM, Hoffmann U et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology (Baltimore, Md) 2010;51:1979–1987.CrossRef
25.
go back to reference Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md) 2004;40:1387–1395.CrossRef Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md) 2004;40:1387–1395.CrossRef
26.
go back to reference Hart-Unger S, Arao Y, Hamilton KJ et al. (2017) Hormone signaling and fatty liver in females: analysis of estrogen receptor alpha mutant mice. Int J Obes (2005) 2017;41:945–954.CrossRef Hart-Unger S, Arao Y, Hamilton KJ et al. (2017) Hormone signaling and fatty liver in females: analysis of estrogen receptor alpha mutant mice. Int J Obes (2005) 2017;41:945–954.CrossRef
27.
go back to reference Koulouri O, Ostberg J, Conway GS. Liver dysfunction in Turner’s syndrome: prevalence, natural history and effect of exogenous oestrogen. Clin Endocrinol 2008;69:306–310.CrossRef Koulouri O, Ostberg J, Conway GS. Liver dysfunction in Turner’s syndrome: prevalence, natural history and effect of exogenous oestrogen. Clin Endocrinol 2008;69:306–310.CrossRef
28.
go back to reference Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007;61:737–747.CrossRef Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007;61:737–747.CrossRef
29.
go back to reference Khan SS, Ning H, Wilkins JT et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol 2018;3:280–287.CrossRef Khan SS, Ning H, Wilkins JT et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol 2018;3:280–287.CrossRef
30.
go back to reference Landi F, Calvani R, Picca A et al. Body Mass Index is Strongly Associated with Hypertension: Results from the Longevity Check-up 7+ Study. Nutrients 2018;10:1976.CrossRef Landi F, Calvani R, Picca A et al. Body Mass Index is Strongly Associated with Hypertension: Results from the Longevity Check-up 7+ Study. Nutrients 2018;10:1976.CrossRef
31.
go back to reference Wang J, Zhang D, Huang R, Li X, Huang W. Gamma-glutamyltransferase and risk of cardiovascular mortality: a dose-response meta-analysis of prospective cohort studies. PloS One 2017;12:e0172631.CrossRef Wang J, Zhang D, Huang R, Li X, Huang W. Gamma-glutamyltransferase and risk of cardiovascular mortality: a dose-response meta-analysis of prospective cohort studies. PloS One 2017;12:e0172631.CrossRef
32.
go back to reference Olubamwo OO, Virtanen JK, Voutilainen A, Kauhanen J, Pihlajamaki J, Tuomainen TP. Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction. Eur J Gastroenterol Hepatol 2018;30:1047–1054.CrossRef Olubamwo OO, Virtanen JK, Voutilainen A, Kauhanen J, Pihlajamaki J, Tuomainen TP. Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction. Eur J Gastroenterol Hepatol 2018;30:1047–1054.CrossRef
33.
go back to reference Calori G, Lattuada G, Ragogna F et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology (Baltimore, Md) 2011;54:145–152.CrossRef Calori G, Lattuada G, Ragogna F et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology (Baltimore, Md) 2011;54:145–152.CrossRef
34.
go back to reference Kim JH, Moon JS, Byun SJ et al. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. Cardiovascular diabetology. 2020;19:51.CrossRef Kim JH, Moon JS, Byun SJ et al. Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. Cardiovascular diabetology. 2020;19:51.CrossRef
35.
go back to reference Jiang ZY, Xu CY, Chang XX et al. Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. BMC Gastroenterol 2013;13:110.CrossRef Jiang ZY, Xu CY, Chang XX et al. Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. BMC Gastroenterol 2013;13:110.CrossRef
36.
go back to reference Yang BL, Wu WC, Fang KC et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PloS One 2015;10:e0120443.CrossRef Yang BL, Wu WC, Fang KC et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PloS One 2015;10:e0120443.CrossRef
37.
go back to reference Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol 2013;11:1201–1204.CrossRef Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol 2013;11:1201–1204.CrossRef
38.
go back to reference Huang X, Xu M, Chen Y et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine. 2015;94:e1682.CrossRef Huang X, Xu M, Chen Y et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine. 2015;94:e1682.CrossRef
40.
go back to reference Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016. J Int Med. 2020. Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016. J Int Med. 2020.
41.
go back to reference Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1209–1222.CrossRef Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014;40:1209–1222.CrossRef
42.
go back to reference Guiu B, Crevisy-Girod E, Binquet C et al. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. Eur Radiol 2012;22:855–863.CrossRef Guiu B, Crevisy-Girod E, Binquet C et al. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy. Eur Radiol 2012;22:855–863.CrossRef
43.
go back to reference Cuthbertson DJ, Weickert MO, Lythgoe D et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol 2014;171:561–569.CrossRef Cuthbertson DJ, Weickert MO, Lythgoe D et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol 2014;171:561–569.CrossRef
Metadata
Title
Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank
Authors
Biyao Zou
Yee Hui Yeo
Ramsey Cheung
Erik Ingelsson
Mindie H. Nguyen
Publication date
01-06-2021
Publisher
Springer US
Keyword
Fatty Liver
Published in
Digestive Diseases and Sciences / Issue 6/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06954-y

Other articles of this Issue 6/2021

Digestive Diseases and Sciences 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.